Cardioprotective actions of the annexin-A1 N-terminal peptide, AC2-26, against myocardial infarction

Cheng Xue Qin, Sarah Rosli, Minh Deo, Nga Cao, Jesse Walsh, Mitchel Tate, Amy E. Alexander, Daniel Donner, Duncan Horlock, Renming Li, Helen Kiriazis, Man K.S. Lee, Jane E. Bourke, Yuan Yang, Andrew J. Murphy, Xiao-Jun Du, Xiao Ming Gao, Rebecca H. Ritchie

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

The anti-inflammatory, pro-resolving annexin-A1 protein acts as an endogenous brake against exaggerated cardiac necrosis, inflammation, and fibrosis following myocardial infarction (MI) in vivo. Little is known, however, regarding the cardioprotective actions of the N-terminal-derived peptide of annexin A1, Ac2-26, particularly beyond its anti-necrotic actions in the first few hours after an ischemic insult. In this study, we tested the hypothesis that exogenous Ac2-26 limits cardiac injury in vitro and in vivo. Firstly, we demonstrated that Ac2-26 limits cardiomyocyte death both in vitro and in mice subjected to ischemia-reperfusion (I-R) injury in vivo (Ac2-26, 1 mg/kg, i.v. just prior to post-ischemic reperfusion). Further, Ac2-26 (1 mg/kg i.v.) reduced cardiac inflammation (after 48 h reperfusion), as well as both cardiac fibrosis and apoptosis (after 7-days reperfusion). Lastly, we investigated whether Ac2-26 preserved cardiac function after MI. Ac2-26 (1 mg/kg/day s.c., osmotic pump) delayed early cardiac dysfunction 1 week post MI, but elicited no further improvement 4 weeks after MI. Taken together, our data demonstrate the first evidence that Ac2-26 not only preserves cardiomyocyte survival in vitro, but also offers cardioprotection beyond the first few hours after an ischemic insult in vivo. Annexin-A1 mimetics thus represent a potential new therapy to improve cardiac outcomes after MI.

Original languageEnglish
Article number269
Number of pages16
JournalFrontiers in Pharmacology
Volume10
DOIs
Publication statusPublished - 3 Apr 2019

Keywords

  • Annexin-A1
  • Cardiac remodeling
  • Formyl peptide receptors
  • Inflammation
  • Myocardial ischemia

Cite this

Qin, Cheng Xue ; Rosli, Sarah ; Deo, Minh ; Cao, Nga ; Walsh, Jesse ; Tate, Mitchel ; Alexander, Amy E. ; Donner, Daniel ; Horlock, Duncan ; Li, Renming ; Kiriazis, Helen ; Lee, Man K.S. ; Bourke, Jane E. ; Yang, Yuan ; Murphy, Andrew J. ; Du, Xiao-Jun ; Gao, Xiao Ming ; Ritchie, Rebecca H. / Cardioprotective actions of the annexin-A1 N-terminal peptide, AC2-26, against myocardial infarction. In: Frontiers in Pharmacology. 2019 ; Vol. 10.
@article{6e7c8a8a35aa462781fa86742ee6c7bb,
title = "Cardioprotective actions of the annexin-A1 N-terminal peptide, AC2-26, against myocardial infarction",
abstract = "The anti-inflammatory, pro-resolving annexin-A1 protein acts as an endogenous brake against exaggerated cardiac necrosis, inflammation, and fibrosis following myocardial infarction (MI) in vivo. Little is known, however, regarding the cardioprotective actions of the N-terminal-derived peptide of annexin A1, Ac2-26, particularly beyond its anti-necrotic actions in the first few hours after an ischemic insult. In this study, we tested the hypothesis that exogenous Ac2-26 limits cardiac injury in vitro and in vivo. Firstly, we demonstrated that Ac2-26 limits cardiomyocyte death both in vitro and in mice subjected to ischemia-reperfusion (I-R) injury in vivo (Ac2-26, 1 mg/kg, i.v. just prior to post-ischemic reperfusion). Further, Ac2-26 (1 mg/kg i.v.) reduced cardiac inflammation (after 48 h reperfusion), as well as both cardiac fibrosis and apoptosis (after 7-days reperfusion). Lastly, we investigated whether Ac2-26 preserved cardiac function after MI. Ac2-26 (1 mg/kg/day s.c., osmotic pump) delayed early cardiac dysfunction 1 week post MI, but elicited no further improvement 4 weeks after MI. Taken together, our data demonstrate the first evidence that Ac2-26 not only preserves cardiomyocyte survival in vitro, but also offers cardioprotection beyond the first few hours after an ischemic insult in vivo. Annexin-A1 mimetics thus represent a potential new therapy to improve cardiac outcomes after MI.",
keywords = "Annexin-A1, Cardiac remodeling, Formyl peptide receptors, Inflammation, Myocardial ischemia",
author = "Qin, {Cheng Xue} and Sarah Rosli and Minh Deo and Nga Cao and Jesse Walsh and Mitchel Tate and Alexander, {Amy E.} and Daniel Donner and Duncan Horlock and Renming Li and Helen Kiriazis and Lee, {Man K.S.} and Bourke, {Jane E.} and Yuan Yang and Murphy, {Andrew J.} and Xiao-Jun Du and Gao, {Xiao Ming} and Ritchie, {Rebecca H.}",
year = "2019",
month = "4",
day = "3",
doi = "10.3389/fphar.2019.00269",
language = "English",
volume = "10",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media",

}

Cardioprotective actions of the annexin-A1 N-terminal peptide, AC2-26, against myocardial infarction. / Qin, Cheng Xue; Rosli, Sarah; Deo, Minh; Cao, Nga; Walsh, Jesse; Tate, Mitchel; Alexander, Amy E.; Donner, Daniel; Horlock, Duncan; Li, Renming; Kiriazis, Helen; Lee, Man K.S.; Bourke, Jane E.; Yang, Yuan; Murphy, Andrew J.; Du, Xiao-Jun; Gao, Xiao Ming; Ritchie, Rebecca H.

In: Frontiers in Pharmacology, Vol. 10, 269, 03.04.2019.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cardioprotective actions of the annexin-A1 N-terminal peptide, AC2-26, against myocardial infarction

AU - Qin, Cheng Xue

AU - Rosli, Sarah

AU - Deo, Minh

AU - Cao, Nga

AU - Walsh, Jesse

AU - Tate, Mitchel

AU - Alexander, Amy E.

AU - Donner, Daniel

AU - Horlock, Duncan

AU - Li, Renming

AU - Kiriazis, Helen

AU - Lee, Man K.S.

AU - Bourke, Jane E.

AU - Yang, Yuan

AU - Murphy, Andrew J.

AU - Du, Xiao-Jun

AU - Gao, Xiao Ming

AU - Ritchie, Rebecca H.

PY - 2019/4/3

Y1 - 2019/4/3

N2 - The anti-inflammatory, pro-resolving annexin-A1 protein acts as an endogenous brake against exaggerated cardiac necrosis, inflammation, and fibrosis following myocardial infarction (MI) in vivo. Little is known, however, regarding the cardioprotective actions of the N-terminal-derived peptide of annexin A1, Ac2-26, particularly beyond its anti-necrotic actions in the first few hours after an ischemic insult. In this study, we tested the hypothesis that exogenous Ac2-26 limits cardiac injury in vitro and in vivo. Firstly, we demonstrated that Ac2-26 limits cardiomyocyte death both in vitro and in mice subjected to ischemia-reperfusion (I-R) injury in vivo (Ac2-26, 1 mg/kg, i.v. just prior to post-ischemic reperfusion). Further, Ac2-26 (1 mg/kg i.v.) reduced cardiac inflammation (after 48 h reperfusion), as well as both cardiac fibrosis and apoptosis (after 7-days reperfusion). Lastly, we investigated whether Ac2-26 preserved cardiac function after MI. Ac2-26 (1 mg/kg/day s.c., osmotic pump) delayed early cardiac dysfunction 1 week post MI, but elicited no further improvement 4 weeks after MI. Taken together, our data demonstrate the first evidence that Ac2-26 not only preserves cardiomyocyte survival in vitro, but also offers cardioprotection beyond the first few hours after an ischemic insult in vivo. Annexin-A1 mimetics thus represent a potential new therapy to improve cardiac outcomes after MI.

AB - The anti-inflammatory, pro-resolving annexin-A1 protein acts as an endogenous brake against exaggerated cardiac necrosis, inflammation, and fibrosis following myocardial infarction (MI) in vivo. Little is known, however, regarding the cardioprotective actions of the N-terminal-derived peptide of annexin A1, Ac2-26, particularly beyond its anti-necrotic actions in the first few hours after an ischemic insult. In this study, we tested the hypothesis that exogenous Ac2-26 limits cardiac injury in vitro and in vivo. Firstly, we demonstrated that Ac2-26 limits cardiomyocyte death both in vitro and in mice subjected to ischemia-reperfusion (I-R) injury in vivo (Ac2-26, 1 mg/kg, i.v. just prior to post-ischemic reperfusion). Further, Ac2-26 (1 mg/kg i.v.) reduced cardiac inflammation (after 48 h reperfusion), as well as both cardiac fibrosis and apoptosis (after 7-days reperfusion). Lastly, we investigated whether Ac2-26 preserved cardiac function after MI. Ac2-26 (1 mg/kg/day s.c., osmotic pump) delayed early cardiac dysfunction 1 week post MI, but elicited no further improvement 4 weeks after MI. Taken together, our data demonstrate the first evidence that Ac2-26 not only preserves cardiomyocyte survival in vitro, but also offers cardioprotection beyond the first few hours after an ischemic insult in vivo. Annexin-A1 mimetics thus represent a potential new therapy to improve cardiac outcomes after MI.

KW - Annexin-A1

KW - Cardiac remodeling

KW - Formyl peptide receptors

KW - Inflammation

KW - Myocardial ischemia

UR - http://www.scopus.com/inward/record.url?scp=85066044619&partnerID=8YFLogxK

U2 - 10.3389/fphar.2019.00269

DO - 10.3389/fphar.2019.00269

M3 - Article

VL - 10

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - 269

ER -